Golcadomide
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2019 (NCT03930953)
Timeline
Indications
Mechanism of action
- E3 ubiquitin-protein ligase HECTD1MODULATOR
HECTD1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CC[C@H](N2C(=O)c3cccc(NCc4ccc(CN5CC(N6CCOCC6)C5)cc4F)c3C2=O)C(=O)N1- Mol. weight
- 535.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095226 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06108232 | Phase 2 | Mar 31, 2024 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT05169515 | Phase 1 | Oct 26, 2022 | Roche |
| NCT04884035 | Phase 1 | Sep 15, 2021 | Bristol-Myers Squibb, Celgene |
| NCT04434196 | Phase 1 | Jun 30, 2020 | Bristol-Myers Squibb, Celgene |
| NCT03930953 | Phase 1 | May 1, 2019 | Celgene |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 0 | 2 | 2020 |
| Celgene | For profit | 3 | 3 | 1 | 2019 |
| Roche | For profit | 1 | 1 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1